Pfizer (PFE) Return on Capital Employed (2009 - 2026)

Pfizer has disclosed Return on Capital Employed across 18 years of filings, most recently posting 10.2% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 467.0% year-over-year to 10.2%; the TTM figure through Mar 2026 stood at 10.2% (down 467.0% YoY), while the FY2025 annual figure was 11.93%, up 3326.0% from the prior year.
• Return on Capital Employed climbed to 10.2% in Q1 2026, from 10.29% in the prior quarter.
• Over the last five years, Return on Capital Employed for PFE reached as high as 37.02% in Q4 2022 and fell as low as 23.16% in Q4 2023.
• The 5-year median for Return on Capital Employed is 9.23% (2024), against an average of 1.17%.
• Annual changes were most pronounced in 2022 — Return on Capital Employed surged 1419 bps — and 2023, when it plunged 4594 bps.
• A 5-year view of Return on Capital Employed shows it stood at 37.02% in 2022, then tumbled by 163 bps to 23.16% in 2023, then jumped by 60 bps to 9.23% in 2024, then slipped by 12 bps to 10.29% in 2025, then rose by 1 bps to 10.2% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 10.2%, 10.29%, and 19.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.